{"created":"2023-06-20T15:47:24.452186+00:00","id":1943,"links":{},"metadata":{"_buckets":{"deposit":"a48fc9e3-ca32-42bc-82b2-6b3b1afa6249"},"_deposit":{"created_by":4,"id":"1943","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"1943"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00001943","sets":["1:11"]},"author_link":["4935"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1989-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"332","bibliographicPageStart":"328","bibliographicVolumeNumber":"41","bibliographic_titles":[{"bibliographic_title":"日本産科婦人科學會雜誌","bibliographic_titleLang":"ja"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Urinastatin (US) 併用補助療法がCDDPによる腎障害抑制に有効であるか否かをCreatinine clearance (Ccr) 値, 尿中Arylamidase (AA) 活性, 尿中γ-glutamyl transpeptidase (γ-GTP) 活性の変化を指標として家兎を以下の7群, すなわち, (1) CDDP 3 mg/kg単独静注, (2) 3%高張食塩水 (15 ml/kg/h, 1h)+CDDP, (3) 3%高張食塩水+CDDP+US (10,000単位/kg), (4) 補液A (350 ml/body)+3%高張食塩水+CDDP, (5) 補液A+3%高張食塩水+CDDP+US, (6) 補液B (200 ml/body)+3%高張食塩水+CDDP, (7) 補液B+3%高張食塩水+CDDP+USに分類しCDDP, 点滴静注投与による腎障害の程度を比較検討した。1. CDDP投与後のCcr値の変化は補液を施行した (4) から (7) 群では補液量にかかわらず変化は認められなかった。一方, 補液を施行しなかった (1) から (3) 群ではCcr値は低下した。2. CDDP投与後の尿中AA活性の変化は (5) と (7) 群のみ変化せず, (1) 群の1, 2, 3日目と (6) 群の1, 2日目は有意 (p<0.05) に高い活性を認めた。上昇率の変化の大きい順から並べると (1), (6), (2), (3), (4), (5), (7) となり, USを併用すれば補液量の少ない (7) 群でも腎障害は充分抑制された。3. CDDP投与後の尿中γ-GTP活性の変化は尿中AA活性とほぼ同様の変化を示し, (5) と (7) 群のみ変化しなかった。上昇率の変化の大きい順は (1), (2), (3), (6), (4), (5), (7) であった。以上より, (5) および (7) 群がCDDPによる腎障害を完全に抑制することができ, 補液量を減少した (7) 群でもCDDPによる腎尿細管細胞の破壊による尿中酵素活性の上昇は認められなかった。すなわち, 補液量を15 ml/kg/hで4時間輸液し, CDDP, 点滴静注時には3%高張食塩水を併用しながら, その直前にUS を2,000単位/kg静注しCDDP投与後に8,000単位/kgを点滴静注すれば完全に腎障害 (chemical nephrotoxicity) を予防することが可能であった。","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本産科婦人科学会","subitem_publisher_language":"ja"}]},"item_3_relation_22":{"attribute_name":"NII論文ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"110002228908","subitem_relation_type_select":"NAID"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 日本産科婦人科学会","subitem_rights_language":"ja"},{"subitem_rights":"本文データは学協会の許諾に基づきCiNiiから複製したものである","subitem_rights_language":"ja"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03009165","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小林, 浩","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"4935","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"sankafujinka-41_3-328.pdf","filesize":[{"value":"433.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"sankafujinka-41_3-328.pdf","url":"https://hama-med.repo.nii.ac.jp/record/1943/files/sankafujinka-41_3-328.pdf"},"version_id":"44f6703d-6563-4d85-9b65-00e4ea6e84bd"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Urinastatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cis-diamminedichloroplatinum","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ovarian cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nephrotoxicity","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Cisplatin腎障害に対するurinastatinの予防効果 : 家兎を用いた実験から","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Cisplatin腎障害に対するurinastatinの予防効果 : 家兎を用いた実験から","subitem_title_language":"ja"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"1943","relation_version_is_last":true,"title":["Cisplatin腎障害に対するurinastatinの予防効果 : 家兎を用いた実験から"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-08-02T07:20:17.581695+00:00"}